Pain Management Drugs Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, Hospital Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pain Management Drugs Market
5.1. COVID-19 Landscape: Pain Management Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pain Management Drugs Market, By Drug Class
8.1. Pain Management Drugs Market, by Drug Class, 2022-2032
8.1.1 NSAIDs
8.1.1.1. Market Revenue and Forecast (2022-2032)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2022-2032)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2022-2032)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2022-2032)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2022-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2022-2032)
Chapter 9. Global Pain Management Drugs Market, By Indication
9.1. Pain Management Drugs Market, by Indication, 2022-2032
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2022-2032)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2022-2032)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2022-2032)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2022-2032)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2022-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2022-2032)
Chapter 10. Global Pain Management Drugs Market, By Distribution Channel
10.1. Pain Management Drugs Market, by Distribution Channel, 2022-2032
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2022-2032)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2022-2032)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2022-2032)
Chapter 11. Global Pain Management Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.1.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.2.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.3.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)
Chapter 12. Company Profiles
12.1. Teva Pharmaceutical
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Endo International
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GlaxoSmithKline
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. AstraZeneca
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Depomed
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Novartis
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample